Publication | Open Access

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Triple CombinationCovid-19 PandemicAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyPharmacotherapyAntiviral DrugMedicineCovid-19Interferon Beta-1b